File card for Exelon makes unsubstantiated superiority claims

Share this article:
A professional file card for Novartis' Exelon makes unsubstantiated superiority claims, overstates the drug's efficacy, includes misleading risk presentations and recommends or suggests an unapproved use, says the FDA. It wants Novartis to submit a plan for circulating corrective materials.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M inVISION